. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Immunol Rev. 2019 May;289(1):186–204. doi: 10.1111/imr.12762

Table 1.

Current FDA-approved chemokine-related therapeutics

Drug class	Drug name	Target	Indication	Potential other uses	References
Small molecule	Tofacitinib	JAK3>>JAK1>JAK2	RA, psoriatic arthritis, UC	Vitiligo, AA	(103, 104, 286, 289, 290, 294)
	Ruxolitinib	JAK½	Myelofibrosis, polycythemia vera	CLE, morphea, RA, vitiligo, AA	(105, 106, 247, 285, 287, 292, 307)
	Baracitinib	JAK½	RA	CLE, morphea, AA, psoriasis	(248, 292, 308–310)
	Oclacitinib	Pan JAK inihbitor	AD	many	(311)
	Maraviroc	CCR5	HIV	Type 1 diseases	(305)
Antibody	Mogamulizumab	CCR4	CTCL	AD	(296–299)